Quarterly Report (10-q)

Date: November 19, 2014

/s/ Guy De Vreese

Guy De Vreese

Chief Executive Officer

(Principal Executive Officer)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2014

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____.

Commission File No. 001-15975

REMEDENT, INC.

(Exact Name of Registrant as Specified in Its Charter)

Nevada		86-0837251
(State or Other Jurisdiction Of Incorporation or Organization)		(I.R.S. Employer Identification Number)

Zuiderlaan 1-3 bus 8, 9000 Ghent, Belgium		N/A
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code 011 32 9 241 58 80

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.

Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( § 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No ¨

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	¨	Accelerated filer	¨

Non-accelerated filer	¨	Smaller reporting company	x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

As of November 19, 2014, there were 19,995,969 outstanding shares of the registrant’s common stock, includes 723,000 shares of treasury stock.

REMEDENT, INC.

FORM 10-Q INDEX

		Page Number

PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Balance Sheets as of September 30, 2014 (Unaudited) and March 31, 2014		1
Consolidated Statements of Operations for the Three and Six Months Ended September 30, 2014 and September 30, 2013 (Unaudited)		2
Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended September 30, 2014 and September 30, 2013 (Unaudited)		3
Consolidated Statements of Cash Flows for the Three and Six Months Ended September 30, 2014 and September 30, 2013 (Unaudited)		4
Notes to Consolidated Financial Statements (Unaudited)		5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		15
Item 3. Quantitative and Qualitative Disclosures About Market Risk		18
Item 4. Controls and Procedures		18

PART II – OTHER INFORMATION
Item 1. Legal Proceedings		18
Item 1A. Risk Factors		18
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		19
Item 3. Defaults Upon Senior Securities		19
Item 4. [Removed and Reserved.]		19
Item 5. Other Information		19
Item 6. Exhibits		20
Signature Page		21

PART I – FINANCIAL INFORMATION

Item 1.

REMEDENT, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	September 30, 2014			March 31, 2014
ASSETS	(unaudited)
CURRENT ASSETS:
Cash and cash equivalents	$	121,198		$	775,286
Accounts receivable, net of allowance for doubtful accounts of $43,410 at September 30, 2014 and $47,469 at March 31, 2014		980,314			787,578
Other Receivable		1,150,000			1,150,000
Inventories, net		539,466			599,251
Prepaid expense		224,064			128,578
Total current assets		3,015,042			3,440,693

PROPERTY AND EQUIPMENT, NET		470,030			489,420
OTHER ASSETS
Investment in GlamSmile Asia Ltd		1,389,280			1,260,150
Investment in MFI (Note 3)		958,652			958,652
Patents, net		13,339			19,579
Total assets	$	5,846,343		$	6,168,494
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
CURRENT LIABILITIES:
Current portion, long term debt	$	2,205,584		$	2,257,403
Line of Credit		—			273,200
Accounts payable		795,078			598,558
Accrued liabilities		266,394			450,303
Deferred revenue		100,565			124,251
Due to related parties		42,987			145,909
Total current liabilities		3,410,608			3,849,624

EQUITY:
Preferred Stock $0.001 par value (10,000,000 shares authorized, none issued and outstanding)		—			—
Common stock, $0.001 par value; (50,000,000 shares authorized, 19,995,969 shares issued and outstanding at September 30, 2014 and March 31, 2014 respectively)		19,996			19,996
Treasury stock, at cost; 723,000 shares outstanding at September 30, 2014 and March 31, 2014 respectively		(831,450	)		(831,450	)
Additional paid-in capital		24,906,269			24,906,269
Accumulated deficit		(20,937,228	)		(21,080,063	)
Accumulated other comprehensive income (loss) (foreign currency translation adjustment)		(874,027	)		(793,382	)
Obligation to issue shares (Note 3)		97,500			97,500
Total Remedent, Inc. stockholders’ equity		2,381,060			2,318,870
Non-controlling interest		54,675			—
Total stockholders’ equity		2,435,735			2,318,870
Total liabilities and equity	$	5,846,343		$	6,168,494

The accompanying notes are an integral part of these consolidated financial statements.

REMEDENT, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the three months ended September 30,						For the six months ended September 30,
	2014			2013			2014			2013

Net sales	$	853,812		$	766,858		$	1,781,978		$	1,466,110
Cost of sales		238,874			254,131			568,275			517,151
Gross profit		614,938			512,727			1,213,703			948,959
Operating Expenses
Research and development		25,448			12,688			39,169			36,285
Sales and marketing		206,612			156,622			432,940			346,003
General and administrative		312,168			310,679			617,660			555,007
Depreciation and amortization		59,772			59,760			118,269			119,303
TOTAL OPERATING EXPENSES		604,000			539,749			1,208,038			1,056,598
INCOME (LOSS) FROM OPERATIONS		10,938			(27,022	)		5,665			(107,639	)
OTHER INCOME (EXPENSES)

Equity income from investments		79,131			43,978			129,131			201,525
Interest expense		(16,123	)		(27,257	)		(35,526	)		(55,875	)
Interest / Other income		9,086			2,940			55,811			10,175
Other deductions		—			(3,793	)		—			(6,481	)
TOTAL OTHER INCOME (EXPENSES)		72,094			15,868			149,416			149,344
NET (LOSS) INCOME		83,032			(11,154	)		155,081			41,705
NET INCOME (LOSS) ATTRIBUTABLE TO NON-CONTROLLING INTEREST		(2,163	)		—			12,246			—

NET INCOME(LOSS) ATTRIBUTABLE TO REMEDENT INC. COMMON SHAREHOLDERS	$	85,195		$	(11,154	)	$	142,835		$	41,705

INCOME (LOSS) PER SHARE
Basic	$	0.00		$	(0.00	)	$	0.00		$	0.00
Fully diluted	$	0.00		$	(0.00	)	$	0.00		$	0.00
WEIGHTED AVERAGE SHARES OUTSTANDING
Basic		19,995,969			19,995,969			19,995,969			19,995,969
Fully diluted		19,995,969			19,995,969			19,995,969			19,995,969

The accompanying notes are an integral part of these consolidated financial statements.

REMEDENT, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited)

	For the three months ended September 30,						For the six months ended September 30,
	2014			2013			2014			2013
Net Income (Loss)	$	85,195		$	(11,154	)	$	142,835		$	41,705
OTHER COMPREHENSIVE INCOME (LOSS):
Foreign currency translation adjustment		(69,564	)		7,111			(80,645	)		12,185
COMPREHENSIVE INCOME (LOSS)	$	15,631		$	(4,043	)	$	62,190		$	53,890

The accompanying notes are an integral part of these consolidated financial statements.

REMEDENT, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the six months ended September 30,
	2014			2013

CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income	$	142,835		$	41,705
Adjustments to reconcile net income (loss) to net cash used by operating activities
Depreciation and amortization		118,269			119,303
Inventory reserve		(40,836	)		4,882
Allowance for doubtful accounts		(4,059	)		266
Equity investment		(129,131	)		(201,525	)
Changes in operating assets and liabilities:
Accounts receivable		(192,736	)		186,893
Inventories		59,785			7,132
Prepaid expenses		(95,486	)		336,643
Accounts payable		179,037			51,689
Accrued liabilities		(183,909	)		(320,912	)
Due to related parties		(102,922	)		—
Deferred revenue		(23,686	)		(29,330	)
Net cash (use by) provided by operating activities		(272,839	)		196,746
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of patent rights		—			(5,869	)
Purchases of equipment		(46,225	)		(70,220	)
Net cash used by investing activities		(46,225	)		(76,089	)
CASH FLOWS FROM FINANCING ACTIVITIES
Net (repayments of) capital leases and notes payable		(93,577	)		(43,356	)
(Repayments of) proceeds from line of credit		(231,442	)		(164,392	)
Net cash provided by financing activities		(325,019	)		(207,748	)
NET (DECREASE) INCREASE IN CASH		(644,083	)		(87,091	)
Effect of exchange rate changes on cash and cash equivalents		(10,005	)		46,513
CASH AND CASH EQUIVALENTS, BEGINNING		775,286			64,504
CASH AND CASH EQUIVALENTS, ENDING	$	121,198		$	23,926
Supplemental Information:
Interest paid	$	10,457		$	30,806
Income taxes paid	$	—		$	—

The accompanying notes are an integral part of these consolidated financial statements.

REMEDENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

DESCRIPTION OF THE COMPANY AND BASIS OF PRESENTATION

The Company is a manufacturer and distributor of cosmetic dentistry products, including a full line of professional dental teeth whitening products which are distributed in Europe, Asia and the United States. The Company manufactures many of its products in Ghent, Belgium as well as outsourced manufacturing in its facility in Beijing, China and in France. The Company distributes its products using both its own internal sales force and through the use of third party distributors.

In these notes, the terms “Remedent”, “Company”, “we”, “us” or “our” mean Remedent, Inc. and all of its subsidiaries, whose operations are included in these consolidated financial statements.

The Company’s financial statements have been prepared on an accrual basis of accounting, in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the periods presented have been reflected herein.

As of September 30, 2014 the Company had a working capital deficit of $395,566 and an accumulated deficit of $20,937,228. Management has taken measures to reduce general expenses and to increase sales prices which should have a positive impact on the results, the cash flow and the liquidity of the Company. Management is also convinced that, in case of necessity, important cash flows can be generated by the sale of investments of the Company. However, additional funding may be required in order to support the Company’s operations and the execution of its business plan. These risks, among others, are also discussed in ITEM 1A – Risk Factors in the Company’s annual report on Form 10-K filed on July 14, 2014 with the SEC. Despite these matters of emphasis, the financial statements have been prepared on a going concern basis.

The Company has conducted a subsequent events review through the date the financial statements were issued, and has concluded that there were no subsequent events requiring adjustments or additional disclosures to the Company's financial statements at September 30, 2014.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accounting policies of the Company, as applied in the interim consolidated financial statements presented herein are substantially the same as presented in the Company’s Form 10-K for the year ended March 31, 2014, except as may be indicated below:

Organization and Principles of Consolidation

The accompanying consolidated financial statements include the accounts of: Remedent N.V. (incorporated in Belgium) located in Ghent , Belgium, Remedent Professional, Inc. and Remedent Professional Holdings, Inc. (both incorporated in California and inactive), Glamtech-USA, Inc. (a Delaware corporation acquired effective August 24, 2008), Remedent N.V.’s 50% owned subsidiary, Biotech Dental Benelux N.V., a Belgium private company located in Ghent, Remedent N.V.’s 51% owned subsidiary, GlamSmile Deutschland GmbH, a German private company located in Munich (effective March 31, 2014 this subsidiary is inactive) and Remedent N.V.’s 80 % owned subsidiary, GlamSmile Rome, an Italian private company located in Rome (effective March 31, 2014 this subsidiary is inactive).

Remedent N.V.’s 21.54 % investment in Glamsmile Dental Technology Ltd., a Cayman Islands company (“Glamsmile Dental”) and its subsidiaries, Glamsmile (Asia) Limited, a company organized and existing under the laws of Hong Kong and a substantially 100 % owned subsidiary of Glamsmile Dental, Beijing Glamsmile Technology Development Ltd., a 100 % owned subsidiary of GlamSmile Asia, its 80% owned subsidiary Beijing Glamsmile Trading Co., Ltd.; and its 98% owned subsidiary Beijing Glamsmile Dental Clinic Co., Ltd., including its 100% owned Shanghai Glamsmile Dental Clinic Co., Ltd., and its 50 % owned Whenzhou GlamSmile Dental Clinic Ltd.,which are accounted for using the equity method after January 31, 2012 (see Note 3 – Long-term Investment)

Remedent, Inc. is a holding company with headquarters in Ghent, Belgium. Remedent Professional, Inc. and Remedent Professional Holdings, Inc. have been dormant since inception.

For all periods presented, all significant inter-company accounts and transactions have been eliminated in the consolidated financial statements and corporate administrative costs are not allocated to subsidiaries.

Interim Financial Information

The interim consolidated financial statements of Remedent, Inc. and Subsidiaries (the “Company”) are condensed and do not include some of the information necessary to obtain a complete understanding of the financial data. Management believes that all adjustments necessary for a fair presentation of results have been included in the unaudited consolidated financial statements for the interim periods presented. Operating results for the six months ended September 30, 2014, are not necessarily indicative of the results that may be expected for the year ended March 31, 2015. Accordingly, your attention is directed to footnote disclosures found in the Annual Report on Form 10-K for the year ending March 31, 2014, and particularly to Note 2, which includes a summary of significant accounting policies.

Warranties

The Company typically warrants its products against defects in material and workmanship for a period of 24 months from shipment.

A tabular reconciliation of the Company’s aggregate product warranty liability for the reporting periods is as follows:

	Six months ended September 30, 2014			Year ended March 31, 2014
Product warranty liability:
Opening balance	$	6,899		$	19,301
Accruals for product warranties issued in the period		(590	)		(12,402	)
Ending liability	$	6,309		$	6,899

Based upon historical trends and warranties provided by the Company’s suppliers and sub-contractors, the Company has made a provision for warranty costs of $6,309 and $6,899 as of September 30, 2014 and March 31, 2014, respectively.

Computation of Earnings (Loss) per Share

Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income (loss) per common share attributable to common stockholders assuming dilution is computed by dividing net income by the weighted average number of shares of common stock outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued.

On April 1, 2009, the Company adopted changes issued by the FASB to the calculation of earnings per share. These changes state that unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities and shall be included in the computation of earnings per share pursuant to the two-class method for all periods presented. The adoption of this change had no impact on the Company’s basic or diluted net loss per share because the Company has never issued any share-based awards that contain non-forfeitable rights.

At each of September 30, 2014 and March 31, 2014, the Company had 19,995,969, shares of common stock issued and outstanding. At September 30, 2014 and March 31, 2014, the Company did not have any warrants outstanding but had 1,795,000 and 1,795,000 options outstanding respectively. As of September 30, 2013, all outstanding options were excluded from the computation of earnings per share because their effect would have been anti-dilutive.

Further, pursuant to ASC 260-10-50-1(c), if a fully diluted share calculation was computed for the three and six month periods ended September 30, 2014 and September 30, 2013 respectively, it would have excluded all options respectively since the Company’s average share trading price during the three month and six month periods ended September 30, 2014 and September 30, 2014 were less than the exercise price of all options.

Comprehensive income (loss) includes all changes in equity except those resulting from investments by owners and distributions to owners, including accumulated foreign currency translation, and unrealized gains or losses on marketable securities.

The Company’s only component of other comprehensive income is the accumulated foreign currency translation consisting of (loss) and gains of $(80,645) and $12,185 for the six months ended September 30, 2014 and 2013, respectively. These amounts have been recorded as a separate component of stockholders’ equity (deficit).

New Accounting Pronouncements

Recently Adopted

The below described accounting guidance has been adopted by the Company effective April 1, 2013 and has not had a material impact upon the Company’s financial condition or results of operations.

In April 2013, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2013-07, Presentation of Financial Statements (Topic 205): Liquidation Basis of Accounting. Under the new standard, an organization will be required to prepare its financial statements using the liquidation basis of accounting when liquidation is “imminent.” Liquidation is considered imminent when the likelihood is remote that the organization will return from liquidation and either (a) a plan for liquidation is approved by the person or persons with the authority to make such a plan effective and the likelihood is remote that the execution of the plan will be blocked by other parties or (b) a plan for liquidation is being imposed by other forces (for example, involuntary bankruptcy). In addition, the new standard provides principles for the recognition and measurement of assets and liabilities and requirements for financial statements prepared using the liquidation method of accounting. The new standard is effective for entities that determine liquidation is imminent during annual periods beginning after December 15, 2013, and interim reporting periods therein. Entities are to apply the requirements prospectively from the day that liquidation becomes imminent, and early adoption is permitted. We are currently unable to determine the impact on our financial statements of the new standard should we be required to adopt it in the future.

LONG-TERM INVESTMENTS

REMEDENT OTC BV

In connection with the restructuring of the Company’s OTC business in December 2008, the Company controlled Remedent OTC BV until September 30, 2011 through its board representations. As agreed upon in the Voting Agreement, after September 30, 2011, the Company had one board representation and consequently no longer controlled its investment in Remedent OTC BV. As such, the financials of Remedent OTC BV are no longer included in the consolidated Financial Statements but accounted for through the equity method. No gain or loss was recorded on the deconsolidation. After September 30, 2011, the Company still owned 50% of Remedent OTC BV.

For the year ended March 31, 2014, the Company recorded an equity Loss of $Nil (2013 - ($149,064) in “Other (expenses) income” for its portion of the net loss recorded by Remedent OTC B.V.

Effective July 13, 2012, and as amended February 7, 2013 the Company sold 100% of its interest in the share capital of Remedent OTC B.V., to an arm’s length party for the total sales price of €950,000 ( $667,300 (€ 500,000), (received during July 2012) and $600,570 (€450,000) was received in February 2013.

GLAMSMILE ASIA LTD.

Acquisition

Effective January 1, 2010 the Company acquired 50.98% of the issued and outstanding shares of Glamsmile Asia Ltd. (“Glamsmile Asia” or “Glamsmile”), a private Hong Kong company, with subsidiaries in Hong Kong and Mainland China, in exchange for the following consideration:

	1.	325,000 Euro (US$466,725). As of March 31, 2011 the full amount was paid.
	2.	250,000 shares of common stock to be issued during the fiscal year ended March 31, 2011 ($97,500 was recorded as an obligation to issue shares as at March 31, 2010). The parties have agreed that the shares will be issued during fiscal year ended March 31, 2015.
	3.	100,000 options on closing (issued);
	4.	100,000 options per opened store at closing (issued);
	5.	100,000 options for each additional store opened before the end of 2011 at the price of the opening date of the store;
	6.	Assumption of Glamsmile’s January 1, 2010 deficit of $73,302.; and
	7.	Repayment of the founding shareholder’s original advances in the amount of $196,599. The balance of $196,599, recorded as due to related parties at March 31, 2010, is unsecured, non-interest bearing and has no specific terms of repayment other than it will be paid out of revenues from Glamsmile, as working capital allows. During the year ended March 31, 2011 a total of $101,245 was paid to the founding shareholder, leaving a balance due of $95,354 on June 27, 2011. As at March 31, 2012 the full amount was paid.

All options reside under the Company’s option plan and are five year options.

Also pursuant to the agreement, the Company granted irrevocable right to Glamsmile Asia to use the Glamsmile trademark in Greater China.

The Company acquired a 50.98% interest in GlamSmile Asia Ltd. (“GlamSmile Asia”) in order to obtain a platform in the Chinese Market to expand and introduce our GlamSmile Asia concept into the Chinese Market. In order to sell into the Chinese Market, an approval by Chinese Authorities is required, in the form of licenses. As GlamSmile Asia was already the owner of such licenses prior to the acquisition, this was an important advantage. We obtained control of GlamSmile Asia through the acquisition of the 50.98% interest and the appointment of our CEO as a Board member of GlamSmile Asia.

On January 30, 2014, the Company has sold a total of 2,500,000 ordinary shares of its investment in GlamSmile Dental Technology Ltd for $3,000,000 and recognized a gain on the sale in the amount of $1,582,597. As of March 31, 2014 the Company has received $1,850,000 and has recorded the balance of $1,150,000 as an amount receivable.

Effective March 31, 2014 the Company has retained a 21.5% ownership in GlamSmile Asia Ltd.

Deconsolidation

On January 28, 2012, the Company entered into a Preference A Shares and Preference A-1 Shares Purchase Agreement (“Share Purchase Agreement”) with Glamsmile Dental Technology Ltd., a Cayman Islands company and a subsidiary of the Company (“Glamsmile Dental”), Glamsmile (Asia) Limited, a company organized and existing under the laws of Hong Kong and a substantially owned subsidiary of Glamsmile Dental, Beijing Glamsmile Technology Development Ltd., Beijing Glamsmile Trading Co., Ltd., Beijing Glamsmile Dental Clinic Co., Ltd., and Shanghai Glamsmile Dental Clinic Co., Ltd., Gallant Network Limited, a shareholder of Glamsmile Dental (“Gallant”), and IDG-Accel China Growth Fund III L.P. (“IDG Growth”), IDG-Accel China III Investors L.P.(“IDG Investors”) and Crown Link Group Limited (“Crown”)(“IDG Growth, IDG Investors and Crown collectively referred to as the “Investors”), pursuant to which the Investors agreed to (i) purchase from the Company an aggregate of 2,857,143 shares of Preference A-1 Shares of Glamsmile Dental, which represents all of the issued and outstanding Preference A-1 Shares of Glamsmile Dental, for an aggregate purchase price of $2,000,000, and (ii) purchase from Glamsmile Dental an aggregate of 5,000,000 shares of Preference A Shares for an aggregate purchase price of $5,000,000.

Under the terms of the Share Purchase Agreement, the Company agreed (a) to indemnify the Investors and their respective affiliates for losses arising out of a breach, or inaccuracy or misrepresentation in any representation or warranty made by the Company or a breach or violation of a covenant or agreement made by the Company for up to $1,500,000, and (b) to transfer 500,000 shares of Glamsmile Dental owned by the Company to the Investors in the event of breach of certain covenants by the Company. In connection with the Share Purchase Agreement, the Company also agreed to enter into an Investor’s Rights Agreement, Right of First Refusal and Co-Sale Agreement, and Voting Agreement with the parties.

In addition, in connection with the contemplated transactions in the Share Purchase Agreement on January 20, 2012, the Company entered into a Distribution, License and Manufacturing Agreement with Glamsmile Dental pursuant to which the Company appointed Glamsmile Dental as the exclusive distributor and licensee of Glamsmile Veneer Products bearing the “Glamsmile” name and mark in the B2C Market in the People’s Republic of China (including Hong Kong and Macau) and Republic of China (Taiwan) and granted related manufacturing rights and licenses in exchange for the original issuance of 2,857,143 shares of Preference A-1 Shares of Glamsmile Dental and $250,000 (the receipt of which was acknowledged as an offset to payment of certain invoices of Glamsmile (Asia) Limited).

On February 10, 2012, the sale of the Preference A-1 Shares and the Preference A Shares was completed. As a result of the closing, the equity ownership of Glamsmile Dental, on an as converted basis, is as follows: 31.4% by the Investors, 39.2 % by Gallant, and 29.4% by the Company. Mr. De Vreese, our chairman, will remain as a director of Glamsmile Dental along with Mr. David Lok, who is the Chief Executive Officer and director of Glamsmile Dental and principal of Gallant. The Investors have a right to appoint one director of Glamsmile Dental, and accordingly the Board of Directors of Glamsmile Dental will consist of Mr. De Vreese, Mr. Lok and a director appointed by the Investors.

In conjunction with the transaction and resulting deconsolidation of Glamsmile Dental, the Company recorded a gain of $1,470,776, calculated as follows:

Consideration received	$	2,000,000
Fair value of 29.4% interest		2,055,884
Carrying value of non-controlling interest		1,117,938
Less: carrying value of former subsidiary’s net assets		(2,002,329	)
Goodwill		(699,635	)
Investment China & Hong Kong		(1,082	)
Rescission agreement Excelsior (Note 11)		(1,000,000	)
	$	1,470,776

For the six month periods ended September 30, 2014 and September 30, 2013 the Company recorded equity income of $129,131 and $201,525 respectively as “Other (expenses) income” for its portion of the net income recorded by GlamSmile Dental Technology Ltd.

MEDICAL FRANCHISES & INVESTMENTS

Effective March 31, 2013, the Company acquired 6.12 % of the issued and outstanding shares of Medical Franchises & Investments N.V., a Belgium corporation ("MFI NV") in exchange for a cash prepayment of $314,778 that was made during the fiscal year ended March 31, 2012. The Company’s investment in 70,334 shares of MFI NV has been recorded at the fair value of $958,652 which is the quoted market price of approximately USD $13.63 (€10.80) per share. Because the investment is being recognized as an available-for-sale investment, an unrecognized gain of $Nil (2013 - $472,561) has been recorded in accumulated other comprehensive income. Future unrealized gains and losses on the investment in MFI will also be recognized in other comprehensive income until realized.

Per ASC-320-10-25-1, investments in debt and equity securities that have readily determinable fair values and are not classified as trading or held-to-maturity securities are classified as available-for-sale securities.

MFI NV has been founded to market an advance in dental technology which has the potential to replace the process of making mechanical impressions of teeth and bite structures with a digital/optical scan.

SHORT TERM LOAN

Effective December 3, 2012, the Company entered into a Loan Agreement (the “Loan Agreement”) with BNP Paribas Fortis Bank, a Belgian Bank, pursuant to which the Company borrowed $132,820 (€100.000). The loan bears interest of 3.68 % per annum and is repayable in 24 equal monthly installments of € 4,331 ($5,465 at the closing rate of September 30, 2014). No additional guaranties (see note 13- secured debt agreements (2)) were required.

As of September 30, 2014 the Company has recorded $16,291 as a current liability. As of September 30, 2013 the Company has recorded $33,947 as a current liability and the balance of $49,378 as long term.

CONCENTRATION OF RISK

Financial Instruments — Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of trade accounts receivable.

Concentrations of credit risk with respect to trade receivables are normally limited due to the number of customers comprising the Company’s customer base and their dispersion across different geographic areas. At September 30, 2014, five customers accounted for 75.70% of the Company’s trade accounts receivables, and two customers accounted for 64.36%. The Company performs ongoing credit evaluations of its customers and normally does not require collateral to support accounts receivable.

Purchases — The Company has diversified its sources for product components and finished goods and, as a result, the loss of a supplier would not have a material impact on the Company’s operations. For the six months ended September 30, 2014 the Company had five suppliers who accounted for 31.65% of accounts payable. For the six months ended September 30, 2013 the Company had five suppliers who accounted for 23.08% of accounts payable.

Revenues — For the six months ended September 30, 2014 the Company had five customers that accounted for 58.63% of total revenues. One of the five customers accounted for 38.79% of total revenues. For the six months ended September 30, 2013 the Company had five customers that accounted for 87.23% of total revenues.

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

The Company’s accounts receivable at period end were as follows:

	September 30, 2014			March 31, 2014
Accounts receivable, gross	$	1,023,724		$	835,047
Less: allowance for doubtful accounts		(43,410	)		(47,469	)
Accounts receivable, net	$	980,314		$	787,578

INVENTORIES

Inventories at period end are stated at the lower of cost (first-in, first-out) or net realizable value and consisted of the following:

	September 30, 2014			March 31, 2014
Raw materials	$	23,697		$	23,760
Components		198,877			228,884
Finished goods		753,558			824,109
		976,132			1,076,753
Less: reserve for obsolescence		(436,666	)		(477,502	)
Net inventory	$	539,466		$	599,251

PREPAID EXPENSES

Prepaid expenses are summarized as follows:

	September 30, 2014		March 31, 2014
Prepaid materials and components	$	167,831	$	45,546
VAT payments in excess of VAT receipts		13,734		11,430
Prepaid rent		34,699		48,293
Other		7,800		23,309
	$	224,064	$	128,578

PROPERTY AND EQUIPMENT

Property and equipment are summarized as follows:

	September 30, 2014			March 31, 2014
Furniture and Fixtures	$	463,892		$	461,260
Machinery and Equipment		1,784,906			1,706,248
		2,248,798			2,167,508
Accumulated depreciation		(1,778,768	)		(1,678,088	)
Property & equipment, net	$	470,030		$	489,420

10.

LINE OF CREDIT

The Company has a mixed-use line of credit facility with BNP Paribas Fortis Bank, a Belgian bank (the “Facility”). The Facility is secured by a first lien on the assets of Remedent N.V. and by personal guarantee of the Company’s CEO.

Effective September 3, 2013 we have agreed to repay our line of credit of € 495.000 (US $624,591) in 10 installments of € 49.500 (US $62,459) + an interest of 3,6 % per year commencing November 1, 2013, with the last payment due on August 1, 2014.

11.

LONG TERM DEBT

Capital Lease Agreements:

On January 15, 2010, the Company entered into a capital lease agreement over a 5 year period for veneer manufacturing equipment totaling €251,903 (US $317,851).

The lease requires a monthly payment of principal and interest at 9.72% and provide for a buyout at the conclusion of the lease terms of 4% of the original value of the contract.

The net book value as of September 30, 2014 and March 31, 2014 of the equipment subject to the foregoing lease was $41,758 and $77,943 respectively.

The following is a schedule by years of future minimum lease payments under capital lease together with the present value of the net minimum lease payments as of September 30, 2014:

Year ending March 31:	$

2015		42,114
Total minimum lease payments		42,114
Less: Amount representing estimated executory costs (such as taxes, maintenance, and insurance), including profit thereon, included in total minimum lease payments		—
Net minimum lease payments		42,114
Less: Amount representing interest (*)		356
Present value of minimum lease payments (**)	$	41,758

* Amount necessary to reduce net minimum lease payments to present value calculated at the Company’s incremental borrowing rate at the inception of the leases.

** Reflected in the balance sheet as current obligations under capital leases of $41,758 and $81,986 respectively.

Secured Debt Agreements (1)

On June 3, 2011, the Company obtained a loan in the principal amount of $1,000,000 (the “Loan”) from an unrelated private company, Excelsior Medical (HK) (“EM”). In connection with the Loan, the Company issued a promissory note, with a simple interest rate of 5% per annum, secured by certain assets of the Company (the “Note”). The maturity date of the Loan is June 3, 2014. Interest of $50,000 per annum is payable in cash on an annual basis.

Effective as of January 11, 2012, the Company entered into a Rescission Agreement with EM and Asia Best Healthcare Co., Ltd. Under the Rescission Agreement, the Company agreed to repay a total of $1,000,000 received under the Distribution Agreement, plus a simple interest rate of 5%, beginning on June 30, 2012, according to the following payment schedule: (i) $250,000 to be paid no later than June 30 , 2012, (ii) $250,000 plus interest on June 30, 2012, (iii) $250,000 plus interest on December 31, 2012, and (iv) $250,000 plus interest on June 30, 2013. The Company also agreed to secure such obligations owed to EM with certain collateral of the Company. During the period ended December 31, 2012 a partial payment of $20,000 in interest has been made. The Company is currently in the process of re-negotiating the terms of repayment.

Secured Debt Agreements (2)

On December 3, 2012, the Company obtained a loan in the principal amount of € 100,000 (the “Loan”) from BNP Paribas Fortis bank, to be repaid over the next 24 months. The loan is secured by a lien on the assets of Remedent N.V. as already granted for the use of our existing Credit Line Facility. The maturity date of the Loan is January 2, 2015 at an interest rate of 3.68% to be repaid in monthly installments of € 4,331 ($5,465).

12.

DUE TO RELATED PARTIES AND RELATED PARTY TRANSACTIONS

Transactions with related parties not disclosed elsewhere in these financial statements consisted of the following:

Compensation:

During the six month periods ended September 30, 2014 and 2013 respectively, the Company incurred $109,517 and $117,673 respectively, as compensation for all directors and officers.

All related party transactions involving provision of services or tangible assets were recorded at the exchange amount, which is the value established and agreed to by the related parties and in management’s opinion reflects arms’ length consideration payable for similar services or transfers.

13.

ACCRUED LIABILITIES

Accrued liabilities are summarized as follows:

	September 30, 2014		March 31, 2014
Accrued employee benefit taxes and payroll	$	208,863	$	358,567
Accrued travel		6,309		7,212
Commissions		35		23,110
Accrued audit and tax preparation fees		4,416		17,938
Reserve for warranty costs		6,309		6,899
Accrued advertising		—		10,153
Accrued interest		—		381
Accrued consulting fees		1,150		1,500
Other accrued expenses		39,312		24,543
	$	266,394	$	450,303

14.

EQUITY COMPENSATION PLANS

As of September 30, 2014, the Company had two equity compensation plans approved by its stockholders (1) the 2004 Incentive and Non-statutory Stock Option Plan (the “2004 Plan”); and (2) the 2007 Equity Incentive Plan (the “2007 Plan”). The Company’s stockholders approved the 2004 Plan reserving 800,000 shares of common stock of the Company pursuant to an Information Statement on Schedule 14C filed with the Commission on May 9, 2005. Finally, the Company’s stockholders approved the 2007 Plan reserving 1,000,000 shares of common stock of the Company pursuant to a Definitive Proxy Statement on Schedule 14A filed with the Commission on October 2, 2007.

In addition to the equity compensation plans approved by the Company’s stockholders, the Company has issued options and warrants to individuals pursuant to individual compensation plans not approved by our stockholders. These options and warrants have been issued in exchange for services or goods received by the Company.

The following table provides aggregate information as of September 30, 2014 with respect to all compensation plans (including individual compensation arrangements) under which equity securities are authorized for issuance.

	2001 Plan					2004 Plan				2007 Plan				Other
	Outstanding Options			Weighted Average Exercise Price		Outstanding Options		Weighted Average Exercise Price		Outstanding Options		Weighted Average Exercise Price		Outstanding Options		Weighted Average Exercise Price

Options outstanding, March 31, 2014		12,500			1.20		432,500		0.96		1,000,000		1.21		350,000		.97
Expired		(12,500	)		—		—		—		—		—		—		—
Options outstanding and exercisable September 30, 2014		—			—		432,500		0.96		1,000,000		1.21		350,000		.97
Exercise price range		—					$0.50 - $2.46			$	1.21				$.39 - 1.75
Weighted average remaining life		—					3.50 years				3.62 years				2.06 years

A summary of the Company’s equity compensation plans approved and not approved by shareholders is as follows:

Plan Category	Number of securities to be issued upon exercise of of outstanding options, warrants and rights		Weighted-average exercise price of outstanding options warrants and rights		Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
Equity Compensation Plans approved by security holders		1,445,000	$	1.17		605,000
Equity Compensation Plans not approved by security holders		820,000	$	.97		NA
Total		2,265,000	$	1.10		605,000

For the six month periods ended September 30, 2014 and September 30, 2013 the Company recognized $Nil (2013— $Nil) in stock based compensation expense in the consolidated statement of operations. No stock options were granted or cancelled/expired in the six month periods ended September 30, 2014 and September 30, 2013.

15.

SEGMENT INFORMATION

The Company’s only operating segment consists of dental products and oral hygiene products sold by Remedent Inc., Remedent N.V., and Biotech Dental Benelux N.V. Our operations are primarily in Europe and Asia and 100% of our sales for the six month periods ended September 30, 2014 and 2013 were generated from customers outside of the United States.

16.

COMMITMENTS

Real Estate Lease:

The Company leases an office facility of 5,187 square feet in Gent, Belgium from an unrelated party pursuant to a nine year lease commencing September 1, 2008 at a base rent of €5,713 per month for the total location ($7,208 per month at September 30, 2014).

Secondly, the Company leases an office facility of 1,991 square feet in Rome, Italy to support the sales and marketing division of our veneer business, from an unrelated third party pursuant to a six year lease commencing July 1, 2011, at a base rent of € 6,500 per month for the total location ($8,969 per month at March 31, 2014). Due to an internal re-organization and in mutual agreement with the unrelated party, the rent agreement was cancelled at March 31, 2014.)

Thirdly, the Company leases an office facility of 635 square feet in Brussels, Belgium from an unrelated party pursuant to a nine year lease commencing July 1, 2012 at a base rent of € 969 per month for the total location ($1,222 per month at September 30, 2014).

Real Estate Lease and All Other Leased Equipment:

Minimum monthly lease payments for real estate, and all other leased equipment are as follows based upon the conversion rate for the (Euro) at September 30, 2014:

March 31, 2015	$	128,883
March 31, 2016		174,249
March 31, 2017		136,022
March 31, 2018		62,426
After five years		47,705
Total:	$	549,285

17.

FINANCIAL INSTRUMENTS

The FASB ASC topic 820 on fair value measurement and disclosures establishes three levels of inputs that may be used to measure fair value: quoted prices in active markets for identical assets or liabilities (referred to as Level 1), observable inputs other than Level 1 that are observable for the asset or liability either directly or indirectly (referred to as Level 2), and unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities (referred to as Level 3).

The carrying values and fair values of our financial instruments are as follows:

			September 30, 2014				March 31, 2014
			Carrying		Fair		Carrying		Fair
	Level		Value		Value		value		value
Cash		1	$	121,198	$	121,198	$	775,286	$	775,286
Accounts receivable		2	$	980,314	$	980,314	$	787,578	$	787,578
Other receivables			$	1,150,000	$	1,150,000	$	1,150,000	$	1,150,000
Long Term investment and advance - GlamSmile Dental Technology Asia		2	$	1,389,280	$	1,389,280	$	1,260,150	$	1,260,150
Long term investments and advances MFI		2	$	958,652	$	958,652	$	958,652	$	958,652
Line of credit		2	$	—	$	—	$	273,200	$	273,200
Short term debt		2	$	2,205,584	$	2,205,584	$	2,257,403	$	2,257,403
Deferred revenue		2	$	100,565	$	100,565	$	124,251	$	124,251
Accounts payable		2	$	795,078	$	795,078	$	598,558	$	598,558
Accrued liabilities		2	$	266,394	$	266,394	$	450,303	$	450,303

The following method was used to estimate the fair values of our financial instruments:

The carrying amount of level 1 and level 2 financial instruments approximates fair value because of the short maturity of the instruments.

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Level 3 financial assets also include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation.

The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no significant transfers between Level 1, Level 2, or Level 3 during the six month periods ended September 30, 2014 or September 30, 2014. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. The following table provides a reconciliation of the beginning and ending balances of the item measured at fair value on a recurring basis in the table above that used significant unobservable inputs (Level 3):

	Six month period ended September 30, 2014
Long term investments and advances:
Beginning balance	$	1,260,150
Gains (losses) included in net loss		129,130
Transfers in (out of level 3)		—

Ending balance	$	1,389,280

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward Looking Statements

The discussion contained herein is for the three and six months ended September 30, 2014 and September 30, 2013. The following discussion should be read in conjunction with the Company’s consolidated financial statements and the notes to the consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2014. In addition to historical information, this section contains “forward-looking” statements, including statements regarding the growth of product lines, optimism regarding the business, expanding sales and other statements. Words such as expects, anticipates, intends, plans, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many factors including continued market acceptance of our products. In addition, actual results could vary materially based on changes or slower growth in the oral care and cosmetic dentistry products market; the potential inability to realize expected benefits and synergies; domestic and international business and economic conditions; changes in the dental industry; unexpected difficulties in penetrating the oral care and cosmetic dentistry products market; changes in customer demand or ordering patterns; changes in the competitive environment including pricing pressures or technological changes; technological advances; shortages of manufacturing capacity; future production variables impacting excess inventory and other risk factors. Factors that could cause or contribute to any differences are discussed in “Risk Factors” and elsewhere in the Company’s annual report on Form 10-K filed on July 14, 2014 with the Securities and Exchange Commission. Except as required by applicable law or regulation, the Company undertakes no obligation to revise or update any forward-looking statements contained in this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2014. The information contained in this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2014 is not a complete description of the Company’s business or the risks associated with an investment in the Company’s common stock. Each reader should carefully review and consider the various disclosures made by the Company in this Quarterly Report on Form 10-Q and in the Company’s other filings with the Securities and Exchange Commission.

Overview

We specialize in the research, development, and manufacturing of oral care and cosmetic dentistry products. We are one of the leading manufacturers of cosmetic dentistry products in Europe. Leveraging our knowledge of regulatory requirements regarding dental products and management’s experience in the needs of the professional dental community, we design, develop, manufacture and distribute our cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia and the United States. We distribute our products using both our own internal sales force and through the use of third party distributors.

Results of Operations

Comparative detail of results as a percentage of sales is as follows:

	For the three months ended September 30,						For the six months ended September 30,
	2014			2013			2014			2013

NET SALES		100.00	%		100.00	%		100.00	%		100.00	%
COST OF SALES		27.98	%		33.14	%		31.89	%		35.27	%
GROSS PROFIT		72.02	%		66.86	%		68.11	%		64.73	%
OPERATING EXPENSES
Research and development		2.98	%		1.65	%		2.20	%		2.47	%
Sales and marketing		24.20	%		20.42	%		24.30	%		23.60	%
General and administrative		36.56	%		40.51	%		34.66	%		37.86	%
Depreciation and amortization		7.00	%		7.79	%		6.64	%		8.14	%
TOTAL OPERATING EXPENSES		70.74	%		70.38	%		67.80	%		72.07	%
INCOME (LOSS) FROM OPERATIONS		1.28	%		(3.52	)%		0.31	%		(7.34	)%
Other income		8.44	%		2.07	%		8.38	%		10.19	%
INCOME (LOSS)		9.72	%		(1.45	)%		8.69	%		2.84	%
NET INCOME (LOSS) ATTRIBUTABLE TO NON- CONTROLLING INTEREST		(0.25	)%		0.00	%		0.69	%		0.00	%
NET INCOME (LOSS) ATTRIBUTABLE TO REMEDENT INC. COMMON SHAREHOLDERS		9.97	%		(1.45	)%		8.00	%		2.84	%

Net Sales

Net sales increased by approximately 11.3% to $853,812 for the three months ended September 30, 2014 as compared to $766,858 for the three months ended September 30, 2013. The increase in sales is primarily due to the first results of our ‘Smile Me Mirror’ and our newly developed software for veneer matching.

Net sales increased by approximately 21.5% to $1,781,978 for the six months ended September 30, 2014 as compared to $1,466,110 for the six months ended September 30, 2013. The increase in sales is primarily due to increased sales of veneers and the sales results of our River 8 and associated software products.

Cost of Sales

Cost of sales decreased approximately 6% to $238,874 for the three months ended September 30, 2014 as compared to $254,131 for the three months ended September 30, 2013. Cost of sales, as a percentage of net sales, has decreased to 27.98 % in the quarter ended September 30, 2014 as compared to 33.14 % in the quarter ended September 30, 2013. The decrease in cost of sales and cost of sales as a percentage of sales is primarily because of our software related products, being the ‘Smile Me Mirror’ and the ‘Veneer Matching’ Software. Now that development is finalized, production costs have decreased.

Cost of sales increased approximately 9.9% to $568,275 for the six months ended September 30, 2014 as compared to $517,151 for the six months ended September 30, 2013. The increase in cost of sales is because of increased sales.

Gross Profit

Our gross profit increased by $102,211 or 19.9% to $614,938 for the three months ended September 30, 2014 as compared to $512,727 for the three months ended September 30, 2013. Our gross profit as a percentage of sales increased to 72.02% in the three months ended September 30, 2014 as compared to 66.86% for the three months ended September 30, 2013. Our gross profit has increased because of our newly launched software related products are achieving improved margins.

Our gross profit increased by $264,744 or 27.9%, to $1,213,703 for the six months ended September 30, 2014 as compared to $948,959 for the six months ended September 30, 2013 primarily because of increased sales and increased pricing of our veneers and higher margins on our associated software products as discussed above.

Operating Expenses

Research and Development. Our research and development expenses increased by $12,760 to $25,448 for the three months ended September 30, 2014 as compared to $12,688 for the three months ended September 30, 2013, an increase of 100.6%. The increase in our research and development costs was primarily because of our final phase in the development of our veneer matching software.

Our research and development costs increased by $2,884 or 7.9% to $39,169 for the six months ended September 30, 2014 as compared to $36,285 for the six months ended September 30, 2013 primarily because of our software related products

Sales and marketing costs. Our sales and marketing costs for the three months ended September 30, 2014 and 2013 were $206,612 and $156,622 respectively, representing an increase of $49,990 or 31.9%. The increase is largely due to the cost of our implant division which is now fully integrated.

Our sales and marketing costs increased by $86,937 or 25.1% to $432,940 for the six months ended September 30, 2014 as compared to $346,003 for the six months ended September 30, 2013.

The increase in sales and marketing costs as compared to the six months ended September 30, 2013 is a result of the integration of our implant division.

General and administrative costs. Our general and administrative costs for the three months ended September 30, 2014 and 2013 were $312,168 and $310,679 respectively, representing an increase of $1,489, or 0.5%. Our general and administrative costs for the six months ended September 30, 2014 and 2013 were $617,660 and $555,007 respectively, representing an increase of $62,653 or 11.3%. The increase in general and administration costs is largely due to the integration of the implant division.

Depreciation and amortization. Our depreciation and amortization increased $59,772 for the three months ended September 30, 2014 as compared to $59,760 for the three months ended September 30, 2013. Our depreciation and amortization decreased $1,034 or 0.9%, to $118,269 for the six months ended September 30, 2014 as compared to $119,303 for the six months ended September 30, 2013. The decrease is because previous investments in machinery and equipment are now fully amortized.

Other income. Our net other income was $72,094 for the three months ended September 30, 2014 as compared to $15,868 for the three months ended September 30, 2013, an increase in other income of $56,226. The increase in other income was primarily because of increased equity income from our investments and decreased interest expense.

Our net other income was $149,416 for the six months ended September 30, 2014 as compared to $149,344 for the six months ended September 30, 2013, an increase in other income of $72.

Internal and External Sources of Liquidity

As of September 30, 2014, we had current assets of $3,015,042 compared to $3,440,693 at March 31, 2014. This decrease of $425,641 was primarily due to a decrease in cash of $654,088, a decrease in inventories of $59,785, offset by an increase in accounts receivable of $192,736, and an increase in prepaid expenses of $95,486. Current liabilities at September 30, 2014 were $3,410,608 as compared to $3,849,624 at March 31, 2014. The decrease in current liabilities of $439,016 was primarily as a result of decreases in our accrued liabilities, line of credit, current portion of long-term debt, deferred revenue, and amounts due to related parties in the amounts of $183,909, $231,442, $93,577, $23,686 and $102,922 respectively, offset by an increase in accounts payable of $196,520.

As of September 30, 2014, we had cash of $121,198. We anticipate that we will need to raise additional funds to satisfy our working capital requirements and implement our business strategy to expand our direct to consumer business model. We intend to continue to look for opportunities to expand the number of GlamSmile Studios in Europe. We will continue to review our expected cash requirements, make all efforts to collect any aged receivables, and take appropriate cost reduction measures to ensure that we have sufficient working capital to fund our operations. In the event additional needs for cash arise, we may seek to raise additional funds from a combination of sources including issuance of debt or equity securities. Additional financing may not be available on terms favorable to us, or at all. Any additional financing activity could be dilutive to our current stockholders. If adequate funds are not available or are not available on acceptable terms, our ability to take advantage of unanticipated opportunities or respond to competitive pressures could be limited.

Cash and Cash equivalents

Our balance sheet at September 30, 2014 reflects cash of $121,198 as compared to $775,286 as of March 31, 2014, a decrease of $654,088.

Operations

Net cash (used by) operations was $($272,839) for the six months ended September 30, 2014 as compared to net cash provided by operations of $196,746 for the six months ended September 30, 2013. The increase of $469,585 in net cash used by operations for the six months ended September 30, 2014 as compared to the six months ended September 30, 2013 is primarily because increased income of $101,130, decreased investment losses of $72,394 and decreases in inventories, increases in accounts payable, and decreased accrued liabilities of $52,653, $127,348 and $137,003 respectively and all of which provided cash), were offset by an increase in inventory reserve of $45,718, increased accounts receivable of $379,629, increased prepaid expenses of $432,129 and decreased amounts due to related parties of $102,922, all of which used cash.

Investing activities

Net cash used in investing activities totaled $46,225 for the six months ended September 30, 2014 as compared to net cash provided by investing activities of $76,089 for the six months ended September 30, 2013. Cash used in the six months ended September 30, 2014 and 2013 was primarily for investing in equipment.

Financing activities

Net cash (used)/provided by financing activities totaled $(325,019) for the six months ended September 30, 2014, as compared to $(207,748) for the three months ended September 30, 2013. The increase in the net cash provided by financing activities in the six month period ended September 30, 2013 of $117,271 was primarily as a result of our decrease in our line of credit.

During the six months ended September 30, 2014 and September 30, 2013, we recognized an increase/ (decrease) in cash and cash equivalents of $(10,005) and $46,513, respectively, from the effect of exchange rates between the Euro and the US Dollar.

Off-Balance Sheet Arrangements

At September 30, 2014, we did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not Applicable.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized, and reported within the required time periods and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objective, and management is required to exercise its judgment in evaluating the cost-benefit relationship of possible controls and procedures..

Management conducted an evaluation, under the supervision and with the participation of the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2014. Based on this evaluation, the Chief Executive Officer and the Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2014.

Changes in Internal Control Over Financial Reporting

There have been no material changes in our internal controls over financial reporting identified in connection with the evaluation of disclosure controls and procedures discussed above that occurred during the quarter ended September 30, 2014 or subsequent to that date that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

To the best knowledge of management, there are no material legal proceedings pending against the Company.

Item 1A. Risk Factors

Not Applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. [Removed and Reserved]

Item 5. Other Information

None.

Item 6. Exhibits

EXHIBIT INDEX

Exhibit No		Description

31.1*		Certifications of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act

31.2*		Certifications of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act

32.1*		Certifications of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act

32.2*		Certifications of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase

101.DEF*		XBRL Taxonomy Extension Definition Linkbase

101.LAB*		XBRL Taxonomy Extension Label Linkbase

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase

__________________

* Filed herewith

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REMEDENT, INC.

Date: November 19, 2014	By:	/s/ Guy De Vreese
		Name:	Guy De Vreese
		Title:	Chief Executive Officer
			(Principal Executive Officer)

Date: November 19, 2014	By:	/s/ Philippe Van Acker
		Name:	Philippe Van Acker
		Title:	Chief Financial Officer
			(Principal Financial and Accounting Officer)

EXHIBIT 31.1

OFFICER’S CERTIFICATE

PURSUANT TO SECTION 302

I, Guy De Vreese, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Remedent, Inc.

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.	The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

		a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

		b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

		c.	Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

		d.	Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5.	The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

		a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

		b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

EXHIBIT 31.2

OFFICER’S CERTIFICATE

PURSUANT TO SECTION 302

I, Philippe Van Acker , certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Remedent, Inc.

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.	The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

		a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

		b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

		c.	Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

		d.	Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5.	The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

		a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

		b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Remedent, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.